MARIETTA, Ga., Sept. 24, 2013 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that Dr. Gary Stanziano has joined MiMedx as the Company's Vice President of Medical Affairs. In his new role, Dr. Stanziano will focus primarily on interfacing with health plans to facilitate broader reimbursement for MiMedx products. "Dr. Stanziano is very knowledgeable in the navigation of the complex healthcare reimbursement system," said Parker H. "Pete" Petit, Chairman and CEO. "He brings a wealth of experience in working with health plans to collaborate on developing effective reimbursement policy and guidelines that ensure reimbursement for appropriate clinical indications and procedures. I have previously worked with Gary for nearly twenty years and have admired his professionalism, clinical expertise and business acumen." Dr. Stanziano previously served as the Vice President of Medical Affairs at Matria Healthcare for twenty years, initially serving in that capacity with Matria's predecessor company, Healthdyne, Inc., and later serving in the same role with Alere, Inc., Matria's successor company. Dr. Stanziano was instrumental in establishing and sustaining Matria's on-going relationships with a large number of health plans that included nearly 1,000 commercial health plan contracts. Dr. Stanziano received his M.D. from the Medical College of Georgia School of Medicine in Augusta, Georgia. He earned a BS degree in Biology and a BS degree in Electrical Engineering from The Georgia Institute of Technology. "Bringing Dr. Stanziano to our organization will allow Dr. Don Fetterolf, our Chief Medical Officer, to focus the majority of his attention on our clinical studies and clinical programs. As we have previously communicated, we have numerous studies that are in progress, just beginning, or in the planning stages. Dr. Fetterolf is an expert in the design, evaluation, reporting and analytics of clinical studies, and his expert focus on these matters will benefit us later in 2014 and 2015," added Bill Taylor, President and COO. In addition to Dr. Fetterolf and Dr. Stanziano, the MiMedx team of Medical Directors consists of Dr. Christopher Clare, who serves as the Company's Consulting Medical Director for Neuroscience, and Dr. Paul Davis, III, who serves as the Company's Consulting Medical Director for Orthopedics. "MiMedx is fortunate to have an accomplished team of Medical Directors with in-depth experience in a wide-range of medical disciplines. Dr. Clare and Dr. Davis provide medical consultation and clinical study advice in their respective specialties, and are vital contributors to these two growth areas for the Company's products," commented Petit. "Each of our Consulting Medical Directors is well respected in his medical field of specialty, and together they provide MiMedx with insight and perspectives relating to two very important medical areas where our dehydrated human amnion/chorion membrane (dHACM) allografts can provide improved clinical and economic outcomes." The contemplated clinical studies will support future reimbursement initiatives for our Section 361 allografts serving these specialties," said Taylor. "Also, as we have stated for over a year, we expect that some future tissue products may be regulated outside of the Section 361 regulatory pathway. These products may need approval via the FDA's Biologics License Applications (BLA) process, which also would require clinical studies."